Palvella Therapeutics, Inc. | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)	Neoplasms by Histologic Type, angiokeratoma, neoplasm, vascular cancer	Recruiting	Phase 2	2026-04-27		NCT07552077
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations	Cutaneous Venous Malformations	Active, not recruiting	Phase 2	2026-03-27		NCT06653842
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations	Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, cardiovascular disorder, lymphangioma, lymphatic system disorder, microcystic lymphatic malformation, neoplasm, vascular malformation	Active, not recruiting	Phase 3	2026-03-27		NCT06239480
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita	Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, ectodermal dysplasia syndrome, hereditary disease, hereditary skin disorder, nail disorder, pachyonychia congenita, skin disorder	Recruiting	Phase 3	2022-12-09		NCT05643872